Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 47: 867-873, 2001;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dajani, L. K.
Right arrow Articles by Warren, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dajani, L. K.
Right arrow Articles by Warren, D. J.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2001;47:867-873.)
© 2001 American Association for Clinical Chemistry, Inc.

Articles

Development of a Rapid and Sensitive Immunofluorometric Assay for Glutathione S-Transferase A

Laila K. Dajania1, Elisabeth Paus1 and David J. Warren1

1 Section for Clinical Pharmacology, Central Laboratory, The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway.

aAuthor for correspondence. Fax 47-22-93-46-86; e-mail laila.dajani{at}klinmed.uio.no.

Background: The short half-life of the {alpha}-class glutathione S-transferases (GSTAs) in plasma combined with their even distribution throughout the liver lobule suggests that they may be useful complements to the more traditionally used liver markers. However, the currently available assays for measuring GSTAs in biological fluids have a poor dynamic range and are cumbersome, requiring multiple steps and prolonged incubation times.

Methods: Hybridomas that secrete monoclonal antibodies to human GSTAs were produced and used to develop a rapid one-step immunometric assay for the determination of GSTA in serum. The assay uses a time-resolved immunofluorometric assay (TR-IFMA) format and requires 35 min of incubation. The reference interval was determined using 208 serum samples from healthy blood donors. We also compared our TR-IFMA with a commercially available enzyme immunoassay (EIA) for GSTAs.

Results: The assay had a detection limit of 0.07 µg/L with a measuring range up to 625 µg/L. Within-run imprecision (CV) was 1.8–2.6% over the concentrations of GSTA tested (2.5–311 µg/L), with a between-run CV of <5%. In healthy blood donors, the median values and reference intervals were 2.0 µg/L and 0.6–7.2 µg/L for females and 2.6 µg/L and 0.7–9.8 µg/L for males, respectively. GSTA concentrations determined with the TR-IFMA correlated well with those obtained using a commercially available EIA.

Conclusions: This report describes a new assay for monitoring the concentrations of GSTAs in human serum. The method may be useful in further evaluating the potential of monitoring serum GSTAs in the routine clinical setting.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Association for Clinical Chemistry.